Open an account

CytomX Therapeutics

CTMX · NASDAQ

$2.51+$0.17 (+7.26%)TodayMarket closed ·
Prev close $2.34

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

Employees
69
Headquarters
South San Francisco, California
Listed
Oct 8, 2015
Sector
Health Care
Industry
Biotechnology
Website
cytomx.com

CTMX key statistics

Market cap
546.93M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.44M
Volume
4.10M
Open price
$2.36
High today
$2.55
Low today
$2.34
52 Week high
$8.21
52 Week low
$2.20

CytomX Therapeutics (CTMX) at a glance

As of Oct 20, 2026, CytomX Therapeutics (CTMX) shares are priced at $2.51, giving the company a market cap of 546.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.34 and $2.55. The current price is 7.3% above the day's low and 1.6% below its high.

Volume so far is 4.10M shares, in line with the average of 3.44M shares a day.

Over the past year CytomX Therapeutics has ranged from $2.20 to $8.21, and now sits 5% of the way up that range.

CytomX Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.0791.

The average analyst price target is $12.68, 405.1% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $12.68
Low
$6.06
Now
$2.51
High
$16.80

CTMX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 117.2% on average.

  1. Q3 FY24: reported $0.07 per share against an estimate of -$0.1756
  2. Q4 FY24: reported $0.23 per share against an estimate of -$0.1996
  3. Q1 FY25: reported $0.27 per share against an estimate of $0.1265
  4. Q2 FY25: reported -$0.001 per share against an estimate of -$0.0782
  5. Q3 FY25: reported -$0.09 per share against an estimate of -$0.0516
  6. Q4 FY25: reported -$0.22 per share against an estimate of -$0.0955
  7. Q1 FY26: reported -$0.10 per share against an estimate of -$0.1232
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.0791

CTMX news

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

  • Press releaseGlobe Newswire

    CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Vandana Singh

    Why Is CytomX Therapeutics Stock Falling On Wednesday?

  • Avi Kapoor

    Crude Oil Down 4%; Dollar Tree Earnings Top Views

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Market-Moving News for March 16th

  • Where CytomX Therapeutics Stands With Analysts

Similar companies

Companies in the same industry as CytomX Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.